Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5281631 | 0.83 | CHRM4 (0.67) | BCHEACHECHRM4 | |
| SCHEMBL3155847 | 0.78 | ACHE (1.00) | BCHEACHECHRM4LMNA | |
| SCHEMBL5278655 | 0.78 | BCHE (0.59) | BCHEACHEHDAC8HDAC6 | |
| SCHEMBL5279913 | 0.76 | BCHE (0.60) | BCHEACHE | |
| SCHEMBL6037898 | 0.75 | TP53 (0.58) | MEN1KMT2AHDAC8HDAC6LMNA | |
| SCHEMBL5289399 | 0.74 | LMNA (0.47) | MEN1KMT2ACHRM4LMNAALDH1A1 | |
| SCHEMBL5291871 | 0.73 | FAAH (0.51) | MEN1KMT2AHDAC8HDAC6CHRM4 | |
| SCHEMBL5289480 | 0.73 | BCHE (0.56) | BCHEACHEKMT2ACHRM4LMNA | |
| SCHEMBL5283344 | 0.73 | HDAC3 (0.53) | MEN1KMT2AHDAC8HDAC6CHRM4 | |
| SCHEMBL5279163 | 0.73 | BCHE (0.50) | BCHEACHEMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | BCHE 1641/4885ACHE 3161/4885MEN1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.